Download Files:
Elacestrant
$180 – $2,520
Products Details
Product Description
– Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].
Web ID
– HY-19822
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C30H38N2O2
Citations
– bioRxiv. 2023 Nov 2.|J Cell Mol Med. 2023 Aug 18.|NPJ Breast Cancer. 2022 Dec 14;8(1):130.|Research Square Preprint. 2023 May 9.|Cancer Discov. 2023 Nov 20.|J Med Chem. 2020 Oct 8;63(19):11085-11099.|Mol Cancer Ther. 2020 Jul;19(7):1395-1405.
References
– [1]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23(16):4793-4804.|[2]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
CAS Number
– 722533-56-4
Molecular Weight
– 458.63
Compound Purity
– 99.80
SMILES
– OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 160 mg/mL (ultrasonic)
Target
– Estrogen Receptor/ERR
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
